Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies (Q33330748)

25 July 2017

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies (English)

1 reference

25 July 2017

0 references

1 reference

M Brada

1

1 reference

25 July 2017

I Judson

2

1 reference

25 July 2017

P Beale

3

1 reference

25 July 2017

S Moore

4

1 reference

25 July 2017

P Reidenberg

5

1 reference

25 July 2017

P Statkevich

6

1 reference

25 July 2017

M Dugan

7

1 reference

25 July 2017

V Batra

8

1 reference

25 July 2017

D Cutler

9

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

British Journal of Cancer

25 July 2017

1 reference

25 July 2017

81

1 reference

25 July 2017

6

1 reference

25 July 2017

1022-1030

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690802

25 July 2017

0 references

cites work

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

In vitro evaluation of temozolomide combined with X-irradiation

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

Activity of temozolomide in the treatment of central nervous system tumor xenografts

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362937

Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/10576660

12 December 2020

inferred from PubMed ID database lookup

Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/10576660

12 December 2020

inferred from PubMed ID database lookup

Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/10576660

12 December 2020

inferred from PubMed ID database lookup

Neck dissection: past, present, future

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690802

7 January 2021

inferred from DOI database lookup

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690802

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6690802

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference